New clinical trials and studies reveal advancements in cancer immunotherapy across multiple tumor types. A Phase II trial showed the combination of nab-paclitaxel and cisplatin outperforming gemcitabine in advanced biliary tract cancer. Meanwhile, Fudan University researchers developed a blood test to predict immunotherapy response in triple-negative breast cancer. Studies also underscore the role of amino acid metabolism in the tumor immune microenvironment, enhancing understanding of tumor-immune interactions and therapeutic targets.